AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15040557
Drug: Malarone (atovaquone/proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malarone (atovaquone/proguanil 3000/1200 mg)
Trial: 11315718
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy regimens (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Trial: 9253783
Drug: Weekly dosing
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dosing of epoetin alfa
Trial: 9253783
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of epoetin alfa
Trial: 8416444
Drug: Single 2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2-g dose of ampicillin
Trial: 3940480
Drug: Prednisolone, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 60 mg/d for 2 weeks, then 30 mg/d for another 2 weeks
Trial: 28123163
Drug: Rivaroxaban 15
RxNorm normalized name: rivaroxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 15 mg twice daily for 21 days during acute treatment phase
Trial: 28123163
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily for up to 12 months after initial treatment
Trial: 22525171
Drug: Patching therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching therapy (1 hour daily per month of age until 8 months, then 50% of waking hours)
Trial: 22525171
Drug: Patching therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching therapy
Trial: 17513629
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 4 g IV
Trial: 17658628
Drug: Acetyl L-carnitine
RxNorm normalized name: Nature's Way Acetyl L-Carnitine Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl L-carnitine (ALC)
Trial: 8053025
Drug: Oral artemisinin
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral artemisinin derivatives in combination with mefloquine for primary treatment of uncomplicated malaria
Trial: 8053025
Drug: Oral artemisinin
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral artemisinin derivatives for treatment of recrudescent infections
Trial: 8053025
Drug: Oral artemisinin
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral artemisinin derivatives for patients with high parasitaemias (> or = 4%) but no clinical evidence of severity
Trial: 8053025
Drug: Parenteral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral formulation of artemether given rectally
Trial: 14752069
Drug: Short chemotherapy
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short chemotherapy (6 months)
Trial: 14752069
Drug: Long chemotherapy
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long chemotherapy (15 months)
Trial: 10510952
Drug: Acarbose (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (100 mg t.d.s.)
Trial: 9090332
Drug: High-dose olanzapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose olanzapine
Trial: 9090332
Drug: Haloperidol (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10-20 mg/day)
Trial: 2945785
Drug: Calcium (1
RxNorm normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1 g elemental calcium/day)
Trial: 12586130
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg/day
Trial: 14516890
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg/day + warfarin
Trial: 6427848
Drug: Lithicarb (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithicarb (standard lithium carbonate preparation)
Trial: 6427848
Drug: Priadel (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priadel (sustained-release lithium carbonate preparation)
Trial: 25466382
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg once daily
Trial: 26800231
Drug: Baricitinib 10
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib 10 mg
Trial: 28474817
Drug: Insulin-treated DM
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated DM (ITDM)
Trial: 28474817
Drug: Non-insulin-treated DM
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin-treated DM (NITDM)
Trial: 25934656
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus stenting
Trial: 20434403
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy alone
Trial: 23296149
Drug: Anti-CD25 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD25 monoclonal antibody (mAb) therapy
Trial: 9827976
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral r‐metHuG‐CSF (filgrastim) administered as a viscous mouthrinse (carboxymethylcellulose 2%, oleum citrii) 4 x 120 microg/day from days 10 to 16.
Trial: 9827976
Drug: Topical oral
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oral r‐metHuG‐CSF (filgrastim)
Trial: 7986112
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with increased dose intensity
Trial: 29531839
Drug: Adjuvant/neoadjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant/neoadjuvant chemotherapy
Trial: 7986112
Drug: Standard adjuvant/neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard adjuvant/neoadjuvant chemotherapy regimens
Trial: 2506834
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy with 30 mg of Mitomycin-C (in 3 doses) and 5 mg/kg/day of 5-FU (1985-1986) or 3 mg/kg/day of 5-FU (1987-1988)
Trial: 2506834
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with the same doses of drugs injected into the peripheral vein
Trial: 2506834
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy with 5 mg/kg/day of 5-FU
Trial: 2506834
Drug: Intraportal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal chemotherapy with 3 mg/kg/day of 5-FU
Trial: 7304488
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of piperazine citrate administered twice within a 2-week period
Trial: 7304488
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of piperazine citrate
Trial: 30119098
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene and cosmetic products (toothpastes, dental tablets, mouthwashes, lip-balms, lipsticks)
Trial: 29443750
Drug: roflumilast 500 μg
RxNorm normalized name: roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: roflumilast 500 μg once daily for 12 months
Trial: 22154766
Drug: Metformin, 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, 2,000 mg/daily
Trial: 14560075
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (primary health care treatment)
Trial: 8227758
Drug: CBZ low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBZ low (15‐25 mumol/l)
Trial: 8227758
Drug: CBZ high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBZ high (28‐40 mumol/l)
Trial: 8227758
Drug: LI (0.6‐0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI (0.6‐0.8 mumol/l)
Trial: 28253878
Drug: Residents' interest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residents' interest in Kampo medicine
Trial: 28253878
Drug: Perceived value
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived value of learning Kampo medicine
Trial: 28253878
Drug: Desire to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desire to learn Kampo medicine
Trial: 28253878
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of Western and Kampo medicine
Trial: 28253878
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of Kampo medicine
Trial: 26448147
Drug: IL–1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL–1 receptor antagonist IL‐1Ra (anakinra)
Trial: 21168369
Drug: AS03(A) adjuvanted
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A) adjuvanted vaccine (3.75 μg of haemagglutinin)
Trial: 21168369
Drug: Whole-virion vaccine
RxNorm normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virion vaccine (7.5 μg of haemagglutinin)
Trial: 19298916
Drug: Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer solution alone; control group, n = 128
Trial: 4069863
Drug: Methylphenidate 5
RxNorm normalized name: dexmethylphenidate 5.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 5 mg
Trial: 15896352
Drug: Methylphenidate 10
RxNorm normalized name: dexmethylphenidate 10.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 10 mg
Trial: 3599565
Drug: Methylphenidate 15
RxNorm normalized name: METHYLPHENIDATE 15MG/9HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 15 mg
Trial: 8188554
Drug: Follow-up dose
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up dose based on trial-phase data
Trial: 3499456
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg body weight)
Trial: 31978372
Drug: Conventional obesity
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional obesity treatment
Trial: 28916667
Drug: IVMT (mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVMT (mechanical thrombectomy combined with intravenous thrombolysis)
Trial: 28916667
Drug: IVT (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVT (intravenous thrombolysis)
Trial: 23930638
Drug: Monitoring without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring without further treatment (Control)
Trial: 15180756
Drug: Omalizumab (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks for 12 months)
Trial: 11871867
Drug: Treatment options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment options for pruritus in cancer patients; specific interventions not detailed.
Trial: 8302503
Drug: Weekly one
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly one hour exercise classes supervised by a physiotherapist
Trial: 30113209
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor intervention (15-minute program: stroking peri‐oral structures for 5 minutes, tongue exercises for 5 minutes, non‐nutritive sucking for 5 minutes, administered once daily for 10 days)
Trial: 30113209
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor intervention
Trial: 21600388
Drug: Oral B(12)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B(12) 1000 μg daily for 90 days
Trial: 21600388
Drug: IM B(12)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM B(12) 1000 μg in 9 injections over 3 months
Trial: 19457640
Drug: Dehydrated cell
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrated cell fraction (DCF) high-dose 120mg
Trial: 19457640
Drug: Dehydrated cell
RxNorm normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrated cell fraction (DCF) low-dose 5mg
Trial: 11207509
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg on-demand therapy
Trial: 11207509
Drug: Placebo on-demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on-demand therapy
Trial: 11207509
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg and Placebo
Trial: 30266677
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine (ID-AraC) plus G-CSF
Trial: 26738812
Drug: PF-03049423 6
RxNorm normalized name: FERMENT COMPLEX 6/PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03049423 6 mg
Trial: 23340738
Drug: Bendamustine 100
RxNorm normalized name: bendamustine 100 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 100 mg/m² on days 1 and 2 of a 4-week cycle
Trial: 23340738
Drug: Fludarabine 25
RxNorm normalized name: fludarabine 25 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m² on days 1 to 5 every 4 weeks
Trial: 19526589
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg intravenously weekly)
Trial: 19229667
Drug: Interferon-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (3 million units subcutaneously three times weekly, escalating to 18 MU)
Trial: 16735934
Drug: lasofoxifene 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lasofoxifene 0.25 mg/day
Trial: 16735934
Drug: lasofoxifene 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lasofoxifene 1.0 mg/day
Trial: 11331428
Drug: Sibutramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (30 mg)
Trial: 7919465
Drug: Natural IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural IFN beta (Frone) administered by intramuscular injection at a dosage of 5 Million Units (MU)/m2 three times weekly for six months
Trial: 7919465
Drug: Natural IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural IFN beta (Frone) administered by intramuscular injection
Trial: 21345600
Drug: 3.6% garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6% garlic treatment group
Trial: 21345600
Drug: 0% garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% garlic treatment group
Trial: 21345600
Drug: 1.8% garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8% garlic treatment group
Trial: 16339606
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution (2.5 mg/kg twice daily)
Trial: 16339606
Drug: Fluconazole oral
RxNorm normalized name: fluconazole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole oral solution or capsules (400 mg daily)
Trial: 12580982
Drug: nelfinavir/ritonavir 2,000/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nelfinavir/ritonavir 2,000/200 mg with a full breakfast
Trial: 12580982
Drug: nelfinavir/ritonavir 2,000/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nelfinavir/ritonavir 2,000/400 mg with a full breakfast
Trial: 12580982
Drug: nelfinavir/ritonavir 2,500/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nelfinavir/ritonavir 2,500/200 mg with a full breakfast
Trial: 10951826
Drug: Carvedilol (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (initial dose 12.5 mg, increased weekly to 75 mg/day)
Trial: 7908570
Drug: Ethamsylate 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethamsylate 12.5 mg/kg intravenously within an hour of delivery, followed by doses at six-hourly intervals for four days (total dose 200 mg/kg)
Trial: 7908570
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.1 mL/kg intravenously
Trial: 7908570
Drug: Ethamsylate 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethamsylate 12.5 mg/kg intravenously
Trial: 29534382
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided quadratus lumborum block with 30 ml 0.33% ropivacaine
Trial: 23760393
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (16 sessions)
Trial: 23760393
Drug: Escitalopram oxalate
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram oxalate (10-20 mg/d)
Trial: 10816183
Drug: Nefazodone (maximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (maximal dose, 600 mg per day)
Trial: 10816183
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Nefazodone + Cognitive behavioral-analysis system of psychotherapy)
Trial: 26694733
Drug: CE 0.45
RxNorm normalized name: Femtrace 0.45mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.45 mg/BZA 20 mg
Trial: 26694733
Drug: CE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.625 mg/BZA 20 mg
Trial: 22737979
Drug: Best practices
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practices primary care plus home-based occupational therapy (24 sessions over 2 years)
Trial: 22737979
Drug: Best practices
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practices primary care plus home-based occupational therapy
Trial: 9845803
Drug: ITF 296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 296 (oral solution)
Trial: 9845803
Drug: ITF 296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 296 (immediate-release tablet)
Trial: 9845803
Drug: ITF 296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 296 (intravenous infusion)
Trial: 9845803
Drug: ITF 296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 296 (oral administration)
Trial: 12401759
Drug: Insulin injection
RxNorm normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin injection
Trial: 338412
Drug: Trasylol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trasylol administered before and after ERCP
Trial: 30958014
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (COMB)
Trial: 28467293
Drug: Belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 10 mg/kg intravenous treatment (concurrent cohort)
Trial: 26077267
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of oral anticoagulation therapy (OAT)
Trial: 19630546
Drug: Enhanced Treatment
RxNorm normalized name: Thera-M Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment (ET) walking intervention
Trial: 19630546
Drug: Minimal Treatment
RxNorm normalized name: Minimally modified low density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Treatment (MT) walking intervention
Trial: 8383012
Drug: pH adjusted
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH adjusted mepivacaine (4 ml sodium bicarbonate added, final pH 7.31)
Trial: 8383012
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (4 ml saline added, final pH 5.6)
Trial: 3533546
Drug: Mexiletine (Mexitil‐Perlongets),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (Mexitil‐Perlongets), 360 mg b.i.d.
Trial: 27707818
Drug: MAG-enriched oil
RxNorm normalized name: magnesium hydroxide / mineral oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAG-enriched oil (500 mg EPA/day and 300 mg DHA/day)